RTGN RetinalGenix Technologies Inc.

OTC Surgical & Medical Instruments & Apparatus DE CIK: 0001836295
AI RATING
STRONG_SELL
95% Confidence

Investment Thesis

RetinalGenix is in acute financial distress with negative stockholders equity of -2.2M against only 7K in assets, indicating technical insolvency. The company has no identifiable revenue, is losing 1.8M annually, and is burning cash at 430K per quarter with only $92 remaining—a trajectory pointing toward imminent collapse or restructuring.

Strengths

Risks

  • ! Negative stockholders equity of -2.2M indicates technical insolvency and going concern risks
  • ! Nearly zero liquidity (7K assets vs 2.2M liabilities; only $92 cash on hand) with no capacity to fund operations
  • ! Severe cash burn of 430K per quarter with no revenue generation; runway exhausted within weeks
  • ! Extreme ROA of -25788.7% demonstrates catastrophic operational failure and value destruction
  • ! No evidence of profitability, revenue generation, or operational viability in latest filings
  • ! Zero insider buying activity in past 90 days suggests no confidence from company leadership

Key Metrics to Watch

Financial Metrics

Revenue
N/A
Net Income
-1.8M
EPS (Diluted)
$-0.10
Free Cash Flow
-430.1K
Total Assets
7.0K
Cash
92.0

Profitability Ratios

Gross Margin N/A
Operating Margin N/A
Net Margin N/A
ROE N/A
ROA -25,788.7%
FCF Margin N/A

Balance Sheet & Liquidity

Current Ratio
0.00x
Quick Ratio
0.00x
Debt/Equity
N/A
Debt/Assets
31,134.6%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: 2026-04-15T04:12:15.019617 | Data as of: 2025-09-30 | Powered by Claude AI